Watch Abera Bioscience AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Abera Bioscience AB (ABERA) stock: price, quality, comparison
Price, quality, revenue and earnings and the peer comparison for Abera Bioscience AB, from audited financials.
Price: kr 7.78. Our models give no reliable value for this company right now (losses, too few models), so we show no fair value.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
AB
Thin data
Oct 29, 2026
Thin data
Oct 29, 2026
Abera Bioscience AB
ABERA · STQuality 30/100
Negative free cash flow
Trails peers (0/6)
Narrow moat 9/100 · thin data
Thin data
No fair value
Watch Abera Bioscience AB for free: we tell you when fair value or trend changes.
Watch for free
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Company profile
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally.
Show moreShow less
The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria.
Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC, Covid-19, and Tuberculosis. The company was incorporated in 2012 and is based in Uppsala, Sweden.
Quality Score breakdown
Overall quality
30/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability
0
How much profit the company makes from its sales and capital
Quality Growth
25
Are margins and returns getting better?
Cashflow
0
Do the profits arrive as real cash?
Financial strength
100
Debt, balance sheet and risk of trouble
Investment
55
Does it invest with discipline instead of growing at any price?
Low Volatility
39
How calm the share price moves, does not count
Momentum
47
Price trend of the last 3 to 12 months, does not count
Near the 52-week high
51
Distance to the 52-week high, does not count
New shares
0
Buys back shares or issues new ones?
Revenue & earnings trend
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Watch ABERA, get fair value alerts →
Compare Abera Bioscience AB with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 598 stocks
Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/B ratio by industry
- Net margin by industry
- Undervalued stocks: Healthcare
- Valuation of the Sweden market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $816.10 | $1,275 | +56% | vs ABERA |
| Vertex Pharmaceuticals Incorporated VRTX | $517.49 | $569.24 | +10% | vs ABERA |
| Samsung Biologics Co 207940 | 1,374,000 KRW | 1,511,400 KRW | +10% | vs ABERA |
| Alnylam Pharmaceuticals, Inc ALNY | $174.00 | $191.40 | +10% | vs ABERA |
| WuXi Biologics (Cayman) Inc 2269 | HK$45.80 | HK$50.38 | +10% | vs ABERA |
| argenx SE ARGX | $882.48 | $908.40 | +3% | vs ABERA |
| CSL Limited CSL | A$196.78 | A$178.75 | −9% | vs ABERA |
| BeOne Medicines AG 6160 | HK$217.60 | HK$153.56 | −29% | vs ABERA |
| Celltrion, Inc 068270 | 188,600 KRW | 74,944 KRW | −60% | vs ABERA |
| Royalty Pharma plc RPRX | $64.76 | $19.01 | −71% | vs ABERA |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
What is the quality score of ABERA?
Abera Bioscience AB has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Abera Bioscience AB (ABERA)?
Abera Bioscience AB reported trailing-twelve-month revenue of about 9.1M SEK (latest available figure, as of Oct 29, 2026).
How solid is the balance sheet of Abera Bioscience AB (ABERA)?
Balance-sheet figures for Abera Bioscience AB (as of Oct 29, 2026): return on equity −163.4%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
Which stocks are comparable to Abera Bioscience AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Abera Bioscience AB (ABERA)?
The closing price on Oct 29, 2026 was kr 7.78. We carry closing prices from our data provider, not a live tick.
Key figures of Abera Bioscience AB
How large is the market capitalisation of Abera Bioscience AB (ABERA)?
The market capitalisation of Abera Bioscience AB is 159M SEK (≈ $16.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Abera Bioscience AB (ABERA)?
The price-to-sales ratio of Abera Bioscience AB is 16.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Abera Bioscience AB (ABERA)?
Earnings per share at Abera Bioscience AB are kr −1.08. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Abera Bioscience AB (ABERA)?
The return on equity (ROE) of Abera Bioscience AB is −163% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Abera Bioscience AB (ABERA)?
On an EBIT basis the return on assets of Abera Bioscience AB is −81.9% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Abera Bioscience AB (ABERA)?
The operating margin of Abera Bioscience AB is −360% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Abera Bioscience AB (ABERA)?
Revenue at Abera Bioscience AB is growing −63.6% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Abera Bioscience AB (ABERA) generate?
The free cash flow of Abera Bioscience AB is −3.7M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Abera Bioscience AB in the live analysis
One click puts Abera Bioscience AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.